| Indicators | Browse All

Cocrystal Pharma, Inc. (COCP)

Healthcare | Biotechnology | Bothell, United States | NasdaqCM
0.96 USD -0.05 (-4.951%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 3:30 a.m. EDT

The short-term outlook remains cautiously bearish due to a persistent lack of upward momentum and a heavy short interest relative to float, suggesting limited organic buying pressure despite the recent price bounce. The long-term investment case is severely compromised by a decade-long structural decline where the stock has lost nearly 99% of its value over nine consecutive years of negative annual returns; this relentless downward trajectory indicates a market consensus that the current business model is failing to generate sustainable value, rendering any current valuation metrics meaningless. There is absolutely no dividend income to offset these massive capital losses, making this a pure speculative vehicle with no income floor.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.189023
MSTL0.189338
AutoETS0.191934
AutoTheta0.318521

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 28%
H-stat 6.40
Ljung-Box p 0.000
Jarque-Bera p 0.024
Excess Kurtosis -0.02
Attribute Value
Sector Healthcare
Debt to Equity Ratio 34.597
Revenue per Share 0.018
Market Cap 13,235,955
Forward P/E -1.50
Beta 1.41
Website https://www.cocrystalpharma.com

Info Dump

Attribute Value
52 Week Change -0.4352941
Address1 19,805 North Creek Parkway
All Time High 1,440.0
All Time Low 0.86
Ask 1.27
Ask Size 2
Average Daily Volume10 Day 27,150
Average Daily Volume3 Month 121,421
Average Volume 121,421
Average Volume10Days 27,150
Beta 1.407
Bid 0.72
Bid Size 2
Book Value 0.299
City Bothell
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.96
Current Ratio 2.664
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 1.01
Day Low 0.96
Debt To Equity 34.597
Display Name Cocrystal Pharma
Dividend Date 1,516,752,000
Earnings Timestamp End 1,755,084,600
Earnings Timestamp Start 1,755,084,600
Ebitda -8,975,000
Ebitda Margins 0.0
Enterprise To Ebitda -1.111
Enterprise To Revenue 44.333
Enterprise Value 9,974,955
Eps Current Year -0.685
Eps Forward -0.64
Eps Trailing Twelve Months -0.72
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.1162
Fifty Day Average Change -0.15619999
Fifty Day Average Change Percent -0.13993907
Fifty Two Week Change Percent -43.529408
Fifty Two Week High 2.67
Fifty Two Week High Change -1.71
Fifty Two Week High Change Percent -0.6404494
Fifty Two Week Low 0.86
Fifty Two Week Low Change 0.099999964
Fifty Two Week Low Change Percent 0.11627903
Fifty Two Week Range 0.86 - 2.67
Financial Currency USD
First Trade Date Milliseconds 1,329,921,000,000
Float Shares 9,124,950
Forward Eps -0.64
Forward P E -1.5
Free Cashflow -4,412,250
Full Exchange Name NasdaqCM
Full Time Employees 10
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -4,841,000
Has Pre Post Market Data 1
Held Percent Insiders 0.30725
Held Percent Institutions 0.05631
Implied Shares Outstanding 13,787,453
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,665,446,400
Last Split Factor 1:12
Long Business Summary Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Long Name Cocrystal Pharma, Inc.
Market us_market
Market Cap 13,235,955
Market State PRE
Max Age 86,400
Message Board Id finmb_49062639
Most Recent Quarter 1,774,915,200
Net Income To Common -8,829,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 13,235,954
Number Of Analyst Opinions 2
Open 1.01
Operating Cashflow -7,593,000
Operating Margins -10.471109
Payout Ratio 0.0
Phone 877 262 7123
Previous Close 1.01
Price Eps Current Year -1.4014598
Price Hint 4
Price To Book 3.2107024
Price To Sales Trailing12 Months 58.826466
Profit Margins 0.0
Quick Ratio 2.443
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.05
Regular Market Change Percent -4.9505
Regular Market Day High 1.01
Regular Market Day Low 0.96
Regular Market Day Range 0.96 - 1.01
Regular Market Open 1.01
Regular Market Previous Close 1.01
Regular Market Price 0.96
Regular Market Time 1,783,972,801
Regular Market Volume 27,146
Return On Assets -0.62441003
Return On Equity -1.54623
Revenue Per Share 0.018
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 13,787,453
Shares Percent Shares Out 0.0293
Shares Short 404,505
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 143,168
Short Name Cocrystal Pharma, Inc.
Short Percent Of Float 0.039100002
Short Ratio 4.01
Source Interval 15
State WA
Symbol COCP
Target High Price 10.0
Target Low Price 8.0
Target Mean Price 9.0
Target Median Price 9.0
Total Cash 4,685,000
Total Cash Per Share 0.34
Total Debt 1,424,000
Total Revenue 225,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.72
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.1067
Two Hundred Day Average Change -0.14669997
Two Hundred Day Average Change Percent -0.13255623
Type Disp Equity
Volume 27,146
Website https://www.cocrystalpharma.com
Zip 98,011